These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37414324)

  • 1. The investigation of interaction and chaperon-like activity of α-synuclein as a protein in pathophysiology of Parkinson's disease upon direct interaction with tectorigenin.
    Tu W; Zheng C; Zheng Y; Feng Z; Lin H; Jiang Y; Chen W; Chen Y; Lee Y; Su J; Zheng W
    Int J Biol Macromol; 2023 Sep; 249():125702. PubMed ID: 37414324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with α-synuclein through hydrophobic interaction.
    Zhu M; H Patel S; Han S
    Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1759-1769. PubMed ID: 28330770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-Synuclein conformation affects its tyrosine-dependent oxidative aggregation.
    Ruf RA; Lutz EA; Zigoneanu IG; Pielak GJ
    Biochemistry; 2008 Dec; 47(51):13604-9. PubMed ID: 19049426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between Copper Chaperone Atox1 and Parkinson's Disease Protein α-Synuclein Includes Metal-Binding Sites and Occurs in Living Cells.
    Horvath I; Blockhuys S; Šulskis D; Holgersson S; Kumar R; Burmann BM; Wittung-Stafshede P
    ACS Chem Neurosci; 2019 Nov; 10(11):4659-4668. PubMed ID: 31600047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potential natural neuroprotective molecules for Parkinson's disease by using chemoinformatics and molecular docking.
    Rondón-Villarreal P; López WOC
    J Mol Graph Model; 2020 Jun; 97():107547. PubMed ID: 32028110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies.
    Tsigelny IF; Sharikov Y; Miller MA; Masliah E
    Nanomedicine; 2008 Dec; 4(4):350-7. PubMed ID: 18640077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on the Molecular Interactions Stabilizing the Structure of α-synuclein Fibril: An In silico Study.
    Sanjeev A; Mattaparthi VSK
    Cent Nerv Syst Agents Med Chem; 2017; 17(3):209-218. PubMed ID: 28460628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Insight into the Binding Profile of DCVJ and α-Synuclein Fibril Revealed by Multiscale Simulations.
    Kuang G; Murugan NA; Ågren H
    ACS Chem Neurosci; 2019 Jan; 10(1):610-617. PubMed ID: 30277753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temperature-dependent structural changes of Parkinson's alpha-synuclein reveal the role of pre-existing oligomers in alpha-synuclein fibrillization.
    Ariesandi W; Chang CF; Chen TE; Chen YR
    PLoS One; 2013; 8(1):e53487. PubMed ID: 23349712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meclofenoxate Inhibits Aggregation of Alpha-synuclein
    Parui A; Biswas S; Roy I
    Protein Pept Lett; 2023; 30(5):361-366. PubMed ID: 36880185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics.
    Coskuner O; Wise-Scira O
    ACS Chem Neurosci; 2013 Jul; 4(7):1101-13. PubMed ID: 23607785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The central theme of Parkinson's disease: α-synuclein.
    Ozansoy M; Başak AN
    Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin induced aggregation of α-synuclein: Insights into the mechanism of drug induced Parkinsonism.
    Garg A; Sinha S
    Colloids Surf B Biointerfaces; 2022 Apr; 212():112371. PubMed ID: 35131711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discerning Modulation of α-Synuclein Amyloid Assembly by α-Crystallin.
    Pippal B; Chaudhuri P; Rani K; Yadav JK; Jain N
    ACS Chem Neurosci; 2023 May; 14(9):1659-1671. PubMed ID: 37057966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation.
    Fonseca-Ornelas L; Eisbach SE; Paulat M; Giller K; Fernández CO; Outeiro TF; Becker S; Zweckstetter M
    Nat Commun; 2014 Dec; 5():5857. PubMed ID: 25524885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease.
    Galvagnion C
    J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-fibrillation potency of caffeic acid against an antidepressant induced fibrillogenesis of human α-synuclein: Implications for Parkinson's disease.
    Fazili NA; Naeem A
    Biochimie; 2015 Jan; 108():178-85. PubMed ID: 25461276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
    Pozo Devoto VM; Falzone TL
    Dis Model Mech; 2017 Sep; 10(9):1075-1087. PubMed ID: 28883016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.